trans,trans-2-(4-Methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-[(N,N-dibutylamino)carbonyl-1-(RS)-ethyl]pyrrolidine-3-carboxylic acid | 173864-35-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: trans,trans-2-(4-Methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-[(N,N-dibutylamino)carbonyl-1-(RS)-ethyl]pyrrolidine-3-carboxylic acid
• 英文别名: 4-Benzo[1,3]dioxol-5-yl-1-(1-dibutylcarbamoyl-ethyl)-2-(4-methoxy-phenyl)-pyrrolidine-3-carboxylic acid；4-(1,3-benzodioxol-5-yl)-1-[1-(dibutylamino)-1-oxopropan-2-yl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid
• CAS: 173864-35-2
• 化学式: C₃₀H₄₀N₂O₆
• 分子量: 524.657
• InChiKey: MUDAUNJNTOHWSU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  38
• 可旋转键数：
  12
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  88.5
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
  申请人：——

  公开号：US20030092757A1

  公开（公告）日：2003-05-15

  Disclosed herein is a method for favorably modulating the health-related quality of life and the health-related quality-adjusted time-to-disease progression in a patient having prostate cancer and a method for measuring of the health-related quality-adjusted time-to-disease progression.

  本文揭示了一种有利地调节患有前列腺癌患者的健康相关生活质量和健康相关质量调整的疾病进展时间的方法，以及一种测量健康相关质量调整的疾病进展时间的方法。
• FAVORABLE MODULATION OF HEALTH-RELATED QUALITY OF LIFE AND HEALTH-RELATED QUALITY-ADJUSTED TIME-TO-PROGRESSION OF DISEASE IN PATIENTS WITH PROSTATE CANCER
  申请人：Abbott Laboratories

  公开号：EP1379238A1

  公开（公告）日：2004-01-14
• [EN] FAVORABLE MODULATION OF HEALTH-RELATED QUALITY OF LIFE AND HEALTH-RELATED QUALITY-ADJUSTED TIME-TO-PROGRESSION OF DISEASE IN PATIENTS WITH PROSTATE CANCER<br/>[FR] MODULATION FAVORABLE DE LA QUALITE DE LA VIE EN LIAISON AVEC LA SANTE ET DE LA PROGRESSION DANS LE TEMPS DE LA MALADIE AJUSTEE PAR LA QUALITE DE LA VIE LIEE A LA SANTE CHEZ DES PATIENTS ATTEINTS DU CANCER DE LA PROSTATE
  申请人：ABBOTT LAB

  公开号：WO2002085351A1

  公开（公告）日：2002-10-31

  Disclosed herein is a method for favorably modulating the health-related quality of life and the health-related quality-adjusted time-to-disease progression in a patient having prostate cancer and a method for measuring of the health-related quality-adjusted time-to-disease progression.